COMMUNIQUÉS West-GlobeNewswire
-
ADARx Pharmaceuticals Announces First Patient Dosed in Phase 3 STOP-HAE Clinical Trial and Orphan Drug Designation for ADX-324, a Long-Acting siRNA in Development for the Prophylactic Treatment of Hereditary Angioedema (HAE)
22/10/2025 -
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
22/10/2025 -
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
22/10/2025
Pages